bpc-157 typical dose mcg clinical trials dosage BPC-157 Dosing (Common Protocols), πΉ Oral / Subcutaneous, β’ 500 daily, β’ Duration: 6 weeks, πΉ Intramuscular / Peritendinous, β’ 1 mg daily, β’ Duration: 6 weeks, β οΈ Note:, Not approved by FDA or bpc 157 injury healing BPC-157
Description
Stopping treatment will make symptoms quickly resurface
Studies have shown that a number of very different neuropsychiatric diseases and symptoms can be completely treated with B12 (1-5)
2021;137(6):e128-e144
Hold it up to a light and you should see straight through without any tint or haze
